Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1555206402
rs1555206402
A 0.700 CausalMutation CLINVAR

dbSNP: rs763059810
rs763059810
0.010 GeneticVariation BEFREE Multivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, diabetes mellitus, hypercholesterolemia, and hyperuricemia revealed that 2 polymorphisms (825C-->T in the G protein beta3 subunit gene and 190G-->A in the CC chemokine receptor 2 gene) were significantly associated with hypertension in men and that one polymorphism (-238G-->A in the tumor necrosis factor alpha gene) was significantly associated with hypertension in women. 12654703

2003

dbSNP: rs76863441
rs76863441
0.010 GeneticVariation BEFREE Multivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia. 14709372

2004

dbSNP: rs5443
rs5443
0.010 GeneticVariation BEFREE Despite the sufficient statistical power, this study could not demonstrate the significant influence of C825T on hyperuricemia or serum uric acid. 16707857

2006

dbSNP: rs1217691063
rs1217691063
0.030 GeneticVariation BEFREE Results from this study suggest that mutation of 5-MTHFR C677T contributes to the higher uric acid levels in both males and females and may be a risk factor for hyperuricemia. 17010581

2007

dbSNP: rs4994
rs4994
0.040 GeneticVariation BEFREE Trp64Arg polymorphism of the beta-3 adrenergic receptor may be independently associated with hyperuricemia in males. 17225053

2007

dbSNP: rs6837293
rs6837293
0.010 GeneticVariation BEFREE In SNP genotyping analysis at the neighbourhood regions of marker D4S3243 for the case-control subjects, the polymorphisms rs7688672 and rs6837293, located on the cGMP-dependent protein kinase II (cGK II) gene, were found to relate significantly to gout disease in a recessive model after adjustment of hyperuricaemia (OR = 2.89, 95% CI 1.19 to 7.02 and OR = 2.72, 95% CI 1.13 to 6.54, respectively). 18678579

2009

dbSNP: rs7688672
rs7688672
0.010 GeneticVariation BEFREE In SNP genotyping analysis at the neighbourhood regions of marker D4S3243 for the case-control subjects, the polymorphisms rs7688672 and rs6837293, located on the cGMP-dependent protein kinase II (cGK II) gene, were found to relate significantly to gout disease in a recessive model after adjustment of hyperuricaemia (OR = 2.89, 95% CI 1.19 to 7.02 and OR = 2.72, 95% CI 1.13 to 6.54, respectively). 18678579

2009

dbSNP: rs893006
rs893006
0.010 GeneticVariation BEFREE The rs893006 polymorphism in SLC22CA12 was confirmed to be a genetic risk for hyperuricaemia among the Chinese male population. 19306160

2009

dbSNP: rs7932775
rs7932775
0.010 GeneticVariation BEFREE These SNPs had a joint additive effect of risk of HUA, with those individuals carrying at least one 'A' allele at the intron 3 SNP and two 'C' alleles at rs7932775 having a 5.88-fold (95% CI 1.25 to 15.57) increased risk of HUA in comparison to those with no risk alleles. 19833602

2010

dbSNP: rs1137070
rs1137070
0.010 GeneticVariation BEFREE We also found that MAOA enzyme activity by rs1137070 allele was associated with hyperuricemia and gout (P for trend = 1.53 x 10(-6) vs. wild-type allele). 19915868

2010

dbSNP: rs1217691063
rs1217691063
0.030 GeneticVariation BEFREE We hypothesized that hyperuricemia would be associated with methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase (TS) 28-bp tandem repeat polymorphism. 19917450

2009

dbSNP: rs4994
rs4994
0.040 GeneticVariation BEFREE Trp64Arg polymorphism of the ADRB3 gene predicted the risk of developing hyperuricemia in this adult population. 20008926

2010

dbSNP: rs2231142
rs2231142
0.800 GeneticVariation BEFREE Associations of the rs2231142 variant with serum uric acid levels and prevalence of gout and hyperuricaemia were examined. 20421215

2010

dbSNP: rs6855911
rs6855911
0.010 GeneticVariation BEFREE The polymorphism rs6855911 in SLC2A9 may be a genetic marker to assess risk of hyperuricemia among Chinese male Han population. 20972595

2011

dbSNP: rs4994
rs4994
0.040 GeneticVariation BEFREE The common polymorphism rs4994 [c. T387C, p. Trp64Arg (W64R)] of the lipolysis regulator beta-3-adrenergic receptor (ADRB3) was identified as a marker in the pathogenesis of hyperuricemia. 21285172

2011

dbSNP: rs1025993235
rs1025993235
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011

dbSNP: rs1209613132
rs1209613132
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011

dbSNP: rs1230053514
rs1230053514
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011

dbSNP: rs189660050
rs189660050
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011

dbSNP: rs727502862
rs727502862
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011

dbSNP: rs753397550
rs753397550
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011

dbSNP: rs1232898090
rs1232898090
0.010 GeneticVariation BEFREE Unadjusted and adjusted multiple logistic regressions showed that the odds ratios (OR) for hyperuricemia were not associated with Pro12Ala polymorphism in PPAR-γ2. 21968942

2012

dbSNP: rs1217691063
rs1217691063
0.030 GeneticVariation BEFREE Although the mechanism of the relationship between the C677T polymorphism and uric acid still remains unclear, these original articles showed that the MTHFR C677T polymorphism may be an independent risk factor for hyperuricemia. 22286863

2012

dbSNP: rs12979860
rs12979860
0.010 GeneticVariation BEFREE Multivariate logistic regression analysis showed that age (OR 1.043, 95% CI 1.012-1.075, p=0.007), triglycerides (OR 1.005, 95% CI 1.000-1.010, p=0.04), hyperuricemia (OR 5.027, 95% CI 1.839-13.742, p=0.002), IL28B rs12979860 TT/TC (OR 0.219, 95% CI 0.101-0.472, p<0.001), and steatosis grade (OR 1.704, 95% CI 1.048-2.773, p=0.03) were independently linked to moderate-severe lobular inflammation. 22314430

2012